KR860005023A - 종양 괴사 인자의 생산 방법 및 종양 괴사 인자의 수율을 증가시키는 방법 - Google Patents

종양 괴사 인자의 생산 방법 및 종양 괴사 인자의 수율을 증가시키는 방법

Info

Publication number
KR860005023A
KR860005023A KR1019850009745A KR850009745A KR860005023A KR 860005023 A KR860005023 A KR 860005023A KR 1019850009745 A KR1019850009745 A KR 1019850009745A KR 850009745 A KR850009745 A KR 850009745A KR 860005023 A KR860005023 A KR 860005023A
Authority
KR
South Korea
Prior art keywords
necrosis factor
tumor necrosis
tnf
yield
increasing
Prior art date
Application number
KR1019850009745A
Other languages
English (en)
Other versions
KR940010865B1 (ko
Inventor
씨.피어스 월터
엠. 프란센 루시아
호노레 레오 타베르니아 얀
로우이세 마리 마르메노트 안네
반 데르 헤이덴 요세
알렛 베르나드
에치. 카와시마 에릭
Original Assignee
비오겐 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 비오겐 인코포레이티드 filed Critical 비오겐 인코포레이티드
Publication of KR860005023A publication Critical patent/KR860005023A/ko
Application granted granted Critical
Publication of KR940010865B1 publication Critical patent/KR940010865B1/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Compounds Of Unknown Constitution (AREA)
KR1019850009745A 1984-12-21 1985-12-23 종양 괴사 인자의 생산 방법 및 종양 괴사 인자의 수율을 증가시키는 방법 KR940010865B1 (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US68459584A 1984-12-21 1984-12-21
US684,595 1984-12-21
US78584785A 1985-10-09 1985-10-09
US785,847 1985-10-09

Publications (2)

Publication Number Publication Date
KR860005023A true KR860005023A (ko) 1986-07-16
KR940010865B1 KR940010865B1 (ko) 1994-11-18

Family

ID=27103367

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019850009745A KR940010865B1 (ko) 1984-12-21 1985-12-23 종양 괴사 인자의 생산 방법 및 종양 괴사 인자의 수율을 증가시키는 방법

Country Status (16)

Country Link
US (1) US5487984A (ko)
EP (3) EP0313104A3 (ko)
JP (4) JP2557053B2 (ko)
KR (1) KR940010865B1 (ko)
AT (1) ATE73856T1 (ko)
AU (2) AU601675B2 (ko)
DE (1) DE3585690D1 (ko)
DK (1) DK399786D0 (ko)
ES (1) ES8705521A1 (ko)
FI (1) FI86194C (ko)
HU (1) HUT40702A (ko)
IE (1) IE58709B1 (ko)
NO (1) NO855216L (ko)
NZ (1) NZ214711A (ko)
PT (1) PT81754B (ko)
WO (1) WO1986003751A2 (ko)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5288852A (en) * 1984-03-06 1994-02-22 Dainippon Pharmaceutical Co., Ltd. Human tumor necrosis factor polypeptides
JPS6248634A (ja) * 1985-07-23 1987-03-03 Mochida Pharmaceut Co Ltd 新規アミノ酸組成物、その製造方法及び該アミノ酸組成物を含有する医療組成物
JPH0698004B2 (ja) * 1985-09-30 1994-12-07 サントリー株式会社 Ｔｎｆ発現用新規プラスミド
US5059530A (en) * 1985-09-30 1991-10-22 Suntory Ltd. Expression vector for human TNF
US4894439A (en) * 1986-05-22 1990-01-16 Cetus Corporation N-terminal derivatives of tumor necrosis factor purified by microporous PTFE membranes
US4677197A (en) * 1985-10-30 1987-06-30 Cetus Corporation Purification method for tumor necrosis factor
NZ219027A (en) * 1986-01-24 1989-09-27 Genentech Inc Antiviral composition containing interferon tumour necrosis factor and/or lymphotoxin
EP0247906B1 (en) * 1986-02-04 1994-12-28 Mizuno, Den'Ichi DNA coding for anti-tumour polypeptides, the polypeptides and anti-tumour agents comprising said polypeptides
US4894225A (en) * 1987-03-02 1990-01-16 Cetus Corporation Combination therapy using antitumor immunotoxins with tumor necrosis factor
GB2217325B (en) * 1988-04-08 1991-11-20 British Bio Technology Synthetic gene for tumour necrosis factor alpha.
AU661652B2 (en) * 1989-10-24 1995-08-03 Chiron Corporation Infective protein delivery system
US6420374B1 (en) 1990-11-30 2002-07-16 Fred Hutchinson Cancer Research Center Use of xanthines as immunosuppressants and to inhibit allograft reactions
US6461851B1 (en) 1992-11-19 2002-10-08 Anticancer, Inc. High expression modules containing two or more tandem copies of a methioninase encoding sequence
US5891704A (en) * 1992-11-19 1999-04-06 Anticancer, Inc. Method to produce high levels of methioninase
US5715835A (en) * 1992-11-19 1998-02-10 Anticancer, Inc. Methods for treating and reducing the potential for cardiovascular disease using methioninase compositions
EP0668933B1 (en) * 1992-11-19 2002-10-02 Anticancer, Inc. Use of methioninase as an antitumor agent in anti-methionine chemotherapy
US5888814A (en) * 1994-06-06 1999-03-30 Chiron Corporation Recombinant host cells encoding TNF proteins
AU3818095A (en) * 1994-10-20 1996-05-15 Industrial Research Limited Separation of amino acids and peptides from protein hydrolysates
AU726486C (en) * 1996-03-14 2004-02-05 Human Genome Sciences, Inc. Human tumor necrosis factor delta and epsilon
US6509170B1 (en) 1996-03-14 2003-01-21 Human Genome Sciences, Inc. Polynucleotides encoding human tumor necrosis factor delta
AU2003236393B2 (en) * 1996-03-14 2006-02-02 Human Genome Sciences, Inc. Methods of Treating or Preventing Inflammation or Rheumatoid Arthritis
AU761216B2 (en) * 1996-03-14 2003-05-29 Human Genome Sciences, Inc. Human tumor necrosis factor delta and epsilon
US7217788B2 (en) * 1996-03-14 2007-05-15 Human Genome Sciences, Inc. Human tumor necrosis factor delta polypeptides
US6541224B2 (en) 1996-03-14 2003-04-01 Human Genome Sciences, Inc. Tumor necrosis factor delta polypeptides
US6617171B2 (en) * 1998-02-27 2003-09-09 The General Hospital Corporation Methods for diagnosing and treating autoimmune disease
US6395273B1 (en) 1998-06-10 2002-05-28 Promega Corporation Prevention and treatment of inflammatory bowel disease
US6599710B1 (en) 1999-03-10 2003-07-29 The General Hospital Corporation Treatment of autoimmune disease
CA2446734A1 (en) * 2001-05-24 2002-11-28 Human Genome Sciences, Inc. Antibodies against tumor necrosis factor delta (april)
US7582313B2 (en) * 2002-06-27 2009-09-01 The General Hospital Corporation Methods of organ regeneration using Hox 11-expressing pluripotent cells
US7628988B2 (en) 2002-06-27 2009-12-08 The General Hospital Corporation Methods and compositions for treating type 1 diabetes
AU2003290948A1 (en) * 2002-11-15 2004-06-15 The General Hospital Corporation Screening methods to identify treatments for autoimmune disease
EP1578799B8 (en) * 2002-12-02 2011-03-23 Amgen Fremont Inc. Antibodies directed to tumor necrosis factor and uses thereof
JP2005132795A (ja) * 2003-10-31 2005-05-26 Genichiro Soma 抗悪性神経膠腫剤及び動物用抗悪性神経膠腫剤
US20080102054A1 (en) * 2005-01-18 2008-05-01 Faustman Denise L Compositions Containing Agm Cells And Methods Of Use Thereof
JP6367836B2 (ja) 2013-02-07 2018-08-01 ザ ジェネラル ホスピタル コーポレイション Ｔ制御性細胞の増殖または枯渇方法
WO2016029043A1 (en) * 2014-08-21 2016-02-25 The General Hospital Corporation Tumor necrosis factor superfamily and tnf-like ligand muteins and methods of preparing and using the same
EP4292664A3 (en) 2015-05-15 2024-06-12 The General Hospital Corporation Antagonistic anti-tumor necrosis factor receptor superfamily antibodies
US11266730B2 (en) 2015-09-29 2022-03-08 The General Hospital Corporation Methods of treating and diagnosing disease using biomarkers for BCG therapy
AU2017263833B2 (en) 2016-05-13 2023-08-03 The General Hospital Corporation Antagonistic anti-tumor necrosis factor receptor superfamily antibodies
CN111747950B (zh) * 2019-03-29 2024-01-23 深圳福沃药业有限公司 用于治疗癌症的嘧啶衍生物

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4332892A (en) 1979-01-15 1982-06-01 President And Fellows Of Harvard College Protein synthesis
NL7903195A (nl) 1979-04-24 1980-10-28 Philips Nv Inrichting voor kunstmatige nagalm.
US4425437A (en) 1979-11-05 1984-01-10 Genentech, Inc. Microbial polypeptide expression vehicle
US4309418A (en) * 1980-03-25 1982-01-05 Sloan-Kettering Research Institute For Cancer Anti-tumor agent from human serum and process
US4338397A (en) 1980-04-11 1982-07-06 President And Fellows Of Harvard College Mature protein synthesis
FI811009L (fi) 1980-06-06 1981-12-07 Biogen Nv Foerbaettrade vektorer foerfaranden foer framstaellning av dessa vektorer och foer expression av klonade gener
SE8204382L (sv) * 1981-07-21 1983-01-22 Hayashibara Biochem Lab Sett att framstella malcellysfaktor och anvendning derav
WO1984001288A1 (en) * 1982-10-06 1984-04-12 Takeshi Makitsubo Process for extracting tumor necrosis factor from macrophage
CA1265444A (en) * 1983-06-27 1990-02-06 Lloyd J. Old Effect of human tumor necrosis factor and human interferon on human cancer cells and methods
JPH0695939B2 (ja) * 1983-12-02 1994-11-30 大日本製薬株式会社 ウサギ癌壊死因子をコ−ドするクロ−ン化ｄνａ
EP0148311B1 (en) * 1983-12-26 1988-07-20 Asahi Kasei Kogyo Kabushiki Kaisha A novel physiologically active polypeptide
JPS60185799A (ja) * 1984-03-06 1985-09-21 Dainippon Pharmaceut Co Ltd ヒト癌壊死因子
EP0155549B1 (en) * 1984-03-06 1991-03-20 Dainippon Pharmaceutical Co., Ltd. Dna encoding human tumor necrosis factor and human tumor necrosis factor polypeptide
US4879226A (en) * 1984-04-06 1989-11-07 Asahi Kasei Kogyo Kabushiki Kaisha Novel human physiologically active polypeptide
IL75318A (en) * 1984-05-31 1994-08-26 Genentech Inc Recombinant human memotoxin and methods for its recombinant production
DE3423234A1 (de) * 1984-06-23 1986-02-06 Boehringer Ingelheim International GmbH, 6507 Ingelheim Synergistische mischungen von interferonen und tumor-nekrose-faktor
GR851626B (ko) * 1984-07-05 1985-11-26 Genentech Inc
US4677064A (en) * 1984-11-09 1987-06-30 Cetus Corporation Human tumor necrosis factor
JPS61124392A (ja) * 1984-11-22 1986-06-12 Asahi Chem Ind Co Ltd 遺伝子組換体の産生する生理活性物質の精製法
US4677663A (en) * 1985-07-05 1987-06-30 Melita Electronic Labs, Inc. Telephone answering and call forwarding improvement
JPH0698004B2 (ja) * 1985-09-30 1994-12-07 サントリー株式会社 Ｔｎｆ発現用新規プラスミド
US5182196A (en) * 1985-10-09 1993-01-26 Biogen, Inc. Expression systems for overproduction of desired proteins

Also Published As

Publication number Publication date
PT81754A (en) 1986-01-02
KR940010865B1 (ko) 1994-11-18
NZ214711A (en) 1991-11-26
PT81754B (pt) 1987-12-30
ES550260A0 (es) 1987-05-01
DK399786A (da) 1986-08-21
JPH07213291A (ja) 1995-08-15
AU5301486A (en) 1986-07-22
WO1986003751A3 (en) 1986-08-14
JP2548525B2 (ja) 1996-10-30
JP2557053B2 (ja) 1996-11-27
US5487984A (en) 1996-01-30
JPH07213292A (ja) 1995-08-15
NO855216L (no) 1986-06-23
AU5510490A (en) 1990-10-25
FI855130A (fi) 1986-06-22
EP0313104A3 (en) 1989-07-12
EP0313104A2 (en) 1989-04-26
DK399786D0 (da) 1986-08-21
IE853273L (en) 1986-06-21
FI86194C (fi) 1992-07-27
EP0368367A1 (en) 1990-05-16
ATE73856T1 (de) 1992-04-15
DE3585690D1 (de) 1992-04-23
FI86194B (fi) 1992-04-15
WO1986003751A2 (en) 1986-07-03
JP2548526B2 (ja) 1996-10-30
HUT40702A (en) 1987-01-28
ES8705521A1 (es) 1987-05-01
JPS62501470A (ja) 1987-06-18
JPH07213293A (ja) 1995-08-15
AU601675B2 (en) 1990-09-20
EP0216786B1 (en) 1992-03-18
FI855130A0 (fi) 1985-12-20
IE58709B1 (en) 1993-11-03
JP2548527B2 (ja) 1996-10-30
EP0216786A1 (en) 1987-04-08

Similar Documents

Publication Publication Date Title
KR860005023A (ko) 종양 괴사 인자의 생산 방법 및 종양 괴사 인자의 수율을 증가시키는 방법
FR2577217B1 (fr) Procede d'hydrogenation de l'acide acetique
FR2564859B1 (fr) Procede de preparation d'acide hyaluronique par fermentation.
FR2597852B1 (fr) Procede de production d'alumine-beta en partant d'alumine-alpha et alumine-beta obtenue par ce procede
BR8405314A (pt) Processo para producao de etanol por fermentacao
AU2624788A (en) Method of purifying protein
FR2501705B1 (fr) Procede de production d'un liant adhesif proteinique vegetal modifie
FR2552424B1 (fr) Procede de preparation de 1,1,1,3,3,3-hexafluoropropane-2-ol par hydrogenolyse de l'hydrate d'hexafluoroacetone
BE888562A (fr) Procede de production d'une preparation enzymatique de fructosyl-transferase,
DE3583245D1 (de) Herstellung von aminosaeuren durch biologischen austausch.
KR860004838A (ko) 결정상태의 글루타민산을 제조하는 방법
FR2552761B1 (fr) Procede de transformation directe d'un aldehyde en un ester ethylenique, nouvelles molecules synthetisees
FR2561645B1 (fr) Procede de preparation d'acides hydroxyalkylaminoacetiques
FR2587035B1 (fr) Procede de production d'ethanol par fermentation de milieux sucres
DE3566534D1 (en) Process for producing an alpha-aromatic group substituted alkanoic acid derivative
FR2500008B1 (fr) Procede pour la production d'acide l-glutamique par fermentation
FR2559778B1 (fr) Procede de preparation de cire punique

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
G160 Decision to publish patent application
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
LAPS Lapse due to unpaid annual fee